Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Leiv Lea - Chief Financial Officer
Richard Miller - Chief Executive Officer
James Rosenbaum - Senior President of Research

Conference Call Participants

Sean Lee - H.C. Wainwright

Operator

Good afternoon, and welcome to the Corvus Pharmaceutical Second Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Aaron Beverlyn [ph]. Please go ahead.

Unidentified Company Representative

Thank you, operator and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals second quarter 2022 update and financial results conference call.

On the call to discuss the business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; and James Rosenbaum, Senior President of Research. The executive team will open the call with some prepared remarks, followed by question-and-answer period.

I would remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus’ quarterly report on Form 10-Q, which was filed today with the SEC and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

With that, I'd like to turn the call over to Leiv Lea. Leiv?

Leiv Lea

Thank you, Aaron. I'll begin with a quick overview of our second quarter